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Abstract Sputuminduction (IS) canbeusedto studyairwayin£ammationin asthmatics andotherlungdiseases.How-
ever, no data are available for patientswith Churg^Strauss syndrome (CSS).A studywas carried outto evaluate eosino-
philcounts andeosinophilcationicprotein (ECP) levelsininduced sputumduring the follow-up ofthreepatientswithCSS.
Induced sputumwas carried out in10 patientswith corticosteroid-dependent asthma (used as a control group).Patients
withCSShad signi¢cantlyhighereosinophilspercentages and ECPlevelsin sputumthanthosewith stable corticosteroid-
dependent asthma.During the follow-up, patients with CSS presented increased ECP levels sputum and eosinophils in
sputum as well as increased blood eosinophils, despite their oral corticosteroid and immunosuppressive treatment.
Eosinophilpercentagein sputumandthetotalnumberofeosinophilsinperipheralbloodweremorepredictive of exacer-
bations of CSSthan sputum ECP.c 2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1163, available online at http://www.idealibrary.comon
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Churg^Strauss syndrome (CSS) is a primary systemic
vasculitis of mainly small and intermediate vessels, with
a propensity for lung involvement (1). Prominent tissue
and blood eosinophilia is one of the de¢ning features of
CSS (2^4).
Oral corticosteroid therapy leads to a dramatic im-
provement both of clinical and radiological signs in both
CSS (5).
Assessment of pulmonary eosinophilia may be as-
sessed by bronchoalveolar lavage (BAL) (2,3). Among
the di¡erent diseases with pulmonary eosinophilia,
the CSS in one of those in which the number of
eosinophils in bronchoalveolar lavage is the largest. Eosi-
nophils and eosinophil cationic protein were also
found to be increased in the BAL £uid of patients
with active CSS.
Sputum induction can be used to study airway in£am-
mation in asthmatics and other diseases. Induced sputum
has not been used in patients with CSS.
The aim of the present study was to compare sputum
eosinophilic in£ammation in three pulmonary diseases
under oral corticosteroid treatment (CSS and cortico-
steroid-dependent asthma).The second aim of the study
was to study whether sputum eosinophilia and sputum
eosinophil cationic protein (ECP) levels weremore accu-Received 25 May 2001and accepted in revised form 31May 2001
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MATERIALANDMETHODS
Patients
The CSS group comprised one woman and two men,
with a median age of 44 years (21^61 years) and a diag-
nosis of CSS according to the1990 American College of
Rheumatology (1). All thesepatientswere taking cortico-
steroids at the time of the study.
Ten patients with corticosteroid-dependent asthma
with a median age of 60 years (50^64 years) were used
as a control group and were selected according to stu-
dies previously (6) (Table1).
Sputum induction andprocessing
Sputum was induced as previously described without
modi¢cation (6). Sputum processing was carried out as
previously published in detail (6).
Bloodprocessing
An aliquot of blood samples was used for total and
di¡erential cell count. Hypereosinophilia was de¢ned as
an absolute blood eosinophil count above 500 cells
mm73.
TABLE 1. Demographic characteristics of the patients
CSS Steroid-dependent asthmatics
Age (years) 44 (21^61) 47 (17^65)
Sex (M/F) 2/l 6/4
FEV1 (% predicted) 71 (40^106) 68 (50^72)
Treatment (% patient)
Inhaled corticosteroids 100 100
Oral corticosteroids 100 100
Immunosupressor 100 0
800 RESPIRATORYMEDICINEBiochemicalmeasurements in sputum
supernatant
The concentration of eosinophilic cationic protein (ECP)
was determinatedusing a commercialradioimmunoassay
kit (RIA; Pharmacia-Upjohn,Uppsala, Sweden) (7).
Study design
Patients were followed-up for 12 months and sputum
induction was carried out every 2 months during clinic
visits in which oral corticosteroids doses were adapted
according to the clinical status and forced expiratory
volume in 1sec (FEV1). Control of CSS was de¢ned de-
pendingon the criteria for asthma published in theGINA
guidelines (8). Patients were considered to have an
exacerbation according to the FACET study (9). Only
severe exacerbations were taken into account. As
previously published (10), visits were classi¢ed as ‘uncon-
trolled visits’ if there had been an exacerbation within
the past15 days preceding sputum induction.Visits were
classi¢ed as ‘controlled visits’ if there had been no ex-
acerbation during this period of time. We compared
eosinophils in blood and eosinophils and ECP in sputum.
RESULTS
Safety of sputum induction
All subjectswell tolerated sputuminduction and satisfac-
tory samples were obtained from all subjects, on all
occasions. No asthma exacerbation and no symptoms
after sputuminductionwas observed.Hypertonic saline-
induced bronchoconstriction was promptly relieved by
the administration of a b2-agonist to all patients.
Sputumcells pro¢le
Eosinophils were detectable in the sputum of all patients
with CSS but in only four of 10 stable corticosteroid-
dependant asthma.Themedian eosinophil countwas 38%
(range 2^89%) in CSS and 3% (range 0^14%) in cortico-
steroid-dependent asthma. ECP levels were detectablein all samples of CSS (range 100^5900mgl71) and in
8/10 corticosteroid-dependent asthmatics (range 0^
350mgl71).
Evolution of eosinophils and ECP during
follow-up
In the three patients followed-up, there were14 exacer-
bations which were associated with an increased blood
eosinophilia (Fig.1,Table1). Sputum eosinophilia and spu-
tum ECP also increased, and there was a greater di¡er-
ence in assessing sputum eosinophil percentages but not
sputum ECP.
DISCUSSION
In this pilot study, we have con¢rmed that the sputum
induction was safe and well tolerated in patients with
severe asthma and CSS. Eosinophils were always
elevated in sputum and blood of CSS patients, and they
were increased during exacerbations. There was an
apparent advantage to measure sputum eosinophils but
not ECP levels by comparison to peripheral blood
eosinophils to assess the control of CSS. However, the
number of patients was low and this study should be
con¢rmedby a larger one.
In the present study, we found that eosinophil counts
in blood and sputum were always increased at all time
points in CSS and that the increase was largely greater
than in cortico-dependent asthmatics, suggesting that
eosinophilic in£ammation in CSS is farmorepronounced
than in cortico-dependent asthma.These results accord
with previous studies on BALwhich showed that eosino-
phil levels are increased in CSS (2^4).
Our study shows that the evaluation of eosinophilic in-
£ammation in induced sputumcouldbe a sensitive tool to
con¢rm the presence of eosinophils in the airway of CSS
and to assess the e¡ect of anti-in£ammatory treatment.
Moreover, there may be some advantage to measuring
airway eosinophils using a non-invasive method which
was always safe in this group of severe patients.
FIG. 1. Eosinophils in peripheralblood and eosinophils and ECP levels in sputumof Churg^Strauss syndromepatients.
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